

# Functional genomics of the prion life cycle

Adriano Aguzzi

University of Zurich

[Adriano.Aguzzi@uzh.ch](mailto:Adriano.Aguzzi@uzh.ch)

*(feel free to take pics, tweet & share as you see fit)*§


# Work performed by:

- Vangelis Bouris
- Davide Caredio
- Elena De Cecco
- Sebastian Hachenberg
- Tingting Liu
- Carlos Oueslati Morales
- Sandesh Neupane
- Stefano Sellitto
- Chiara Trevisan
- Dalila Laura Vena
- Hao Wang
- Yancheng Wu
- Jiang-An Yin

# The rationale for unbiased genetic perturbations


- Therapy of neurodegeneration is held back by a **dearth of actionable targets**.
  - For prions, I see only PrP.
  - For AD, PD and ALS, I see  $\leq 4$  plausible targets each.
- For decades, neurodegeneration research has been hypothesis-driven. It's time to explore hypothesis-free approaches.
- Case in point: **metabolic syndrome and alcohol addiction**
  - 50 years of hypothesis-based lifestyle interventions haven't yielded much
  - GLP-1 agonists came out of serendipity, and are having a huge impact
- **How can we speed up serendipity?**

# The prion life cycle




# PrP<sup>C</sup> transduces prion toxicity!!!

- Grafts develop prion disease
- *Prnp*<sup>0/0</sup> hosts stay healthy.



Brandner etc,  
Nature 1996



11.10.94

PrP<sup>Sc</sup> 10<sup>6</sup>g  
in TBS - 81j.  
37°C, 6 units.

2850
3707
3661
3658
3455
3716
3715
3714
3739

30' Sect. und.


(9.9.94)

12.10.94

# Selective vulnerability to prions of different cell types



Synthetic lethality




Maybe they lack  
some toxicity  
transducers?




**Tingting Liu**  
**Jiang-An Yin**


# Programmable gene activation by CRISPR-a



# CRISPR-activation synthetic-lethal screen for transducers of prion toxicity



# Ciliogenesis correlates with prion toxicity




Tingting Liu  
Jiang-An Yin

# What is the primary cilium, and why is it there?

**Trafficking**  
IFT complexes  
BBSome  
Motors

**Motility**  
Central pair microtubules  
Radial spokes  
Nexin-dynein regulatory complex  
Outer and inner dynein arms





**Structure and signaling**  
Axoneme  
Ciliary membrane  
Signalling complexes

**Assembly and compartmentalization**  
Centriole  
Distal appendages  
Subdistal appendages  
Transition zone  
Centriolar satellites

# Validation in organotypic slice cultures (COCS)

*Prion infection*

*8 wks*





*Normal morphology*




*Cerebellar granule cell degeneration*

# Inhibition of ciliogenesis rescues prion-induced neurodegeneration *ex vivo*




**HPI-4:** Hedgehog antagonist inhibits ciliogenesis


# Inhibition of ciliogenesis rescues prion-induced neurodegeneration *ex vivo*



# Inhibition of ciliogenesis with Centrinone-B blocks prion toxicity



COCS at 55 days post culturing





# Inhibition of HTR6 alleviates prion toxicity



DMSO

SB258585


NBH



RML6



HTR6, serotonin receptor 6




Cultured organotypic cerebellum slice (COCS)

51 days post culturing;

SB258585 : HTR6 specific inhibitor.

# Inhibition of ciliogenesis targets prion-induced toxicity but does not reduce PK-resistant prion protein *in sectione*



Centrinone-B: ciliogenesis inhibitor targeting PLK4;


Calb2: Granular cell marker;

Cerebellum slices (Tga20, Prnp over-expressed strain) at 55 days post culturing

# Next-generation **arrayed** libraries - why???



1. Pooled libraries are good for lethality screening, but inadequate for **biochemical, morphological** and **non-autonomous phenotypes**.
2. Single sgRNA efficacy is low, variable and unpredictable.
3. Most libraries disregard DNA polymorphisms among humans.

# Arrayed libraries for indexed genome-wide CRISPRcut, CRISPRact and CRISPRoff screens



- 4 sgRNA/plasmid
- Lentiviral backbone
- PiggyBac transposon elements
- Puromycin and blue-fluorescent protein markers
- Designed to be tolerant to the most common human genetic polymorphisms.

# APPEAL does not require agarose colony picking



## 19'820 CRISPRo plasmids (T.spiezzo)





## 22'326 CRISPRa plasmids (T.gonfio)




Jiang-An Yin et al.  
Nature Biomedical Engineering, 2024

# High-throughput high-titer lentivirus production



# 4sgRNAs are better than 1 sgRNA



# Glucocerebrosidase and Parkinson's disease

*GBA* mutations are the most common genetic risk factor for PD development (independent of GD)

**Incomplete penetrance:** not all *GBA* mutation carriers develop PD (~10-30% by age 70)



→ Genetic modifiers most likely contribute to disease development and phenotype in GD and PD!

Kathi Ging, Jiang-An Yin et al.


*npj Parkinsons Dis.* **10**, 192 (2024)

<https://doi.org/10.1038/s41531-024-00819-7>




# A genome-wide arrayed activation screen for GBA modifiers




# Excellent separation between negative and positive controls



# Genome wide modifiers of GCaSe



# Human chorionic gonadotropin (hCG) and PD




## Parkinson's Disease in Pregnancy: A Case Report and Review of the Literature



Sara Olivola<sup>1\*</sup>, Serena Xodo<sup>1</sup>, Enrica Olivola<sup>2</sup>, Fabiana Cecchini<sup>1</sup>, Ambrogio Pietro Londero<sup>1</sup> and Lorenza Driul<sup>1</sup>

<sup>1</sup> Department of Gynaecology and Obstetrics, School of Medicine of Udine, Udine, Italy; <sup>2</sup> IRCCS Istituto Neurologico Mediterraneo (INM) Neuromed, Pozzilli, Italy

**CGB, CGB5, CGB7, CGB8**





Kristiina Rull and Maris Laan, 2005




Janet Choi and Johan Smitz, 2014

Jiang-An Yin et al unpublished


# Optical CRISPR screen for modifiers of $\alpha$ -Synuclein aggregation




An arrayed screen in  
384-well plate




$\alpha$ -Synuclein Preformed Fibrils  
Treatment



Immunostaining with  
anti-pSer129 Antibody



Hit validation in neuronal and  
animal models




Data analysis and Hits Selection




High-throughput Imaging and  
Image Analysis

# Image Analysis Pipeline


## Identification and quantification of cells positive for a-synuclein aggregates



1. Pixel classification and objects segmentation (nuclei and fibrils)
2. Secondary objects segmentation (cells)
3. Quantification of total cells
4. Quantification of cells that contain fibrils



Athena Economides



173 lines (122 loc) · 5.85 KB


Preview Code Blame

Raw Copy Download Edit

# aSynAggreCount

A codebase for automated analysis of High Content Screens.



The input image-data are assumed to be generated from High Content Screen plates, with multiple fields of view acquired per well, and 3 channels recorded per field, corresponding to nuclei, cells, and aggregates. For a 384-well plate with 9 fields per well, 10'368 images are acquired in total per plate which are processed by the **aSynAggreCount** package to quantify aggregate-positive cells. For each image, **aSynAggreCount** performs image pre-processing to correct for the presence of uneven illumination and digitization noise, then performs segmentation of the structures of interest (nuclei, cells, aggregates), and finally applies co-localization analysis to characterize the presence of aggregates inside cells. An illustration of the image processing pipeline is shown below.



Athena Economidou

<https://github.com/aecon/AggreQuant>

# Genome-wide screen



# Quality control: SSMD score




Plate number

$$SSMD = \frac{\bar{X}_P - \bar{X}_N}{\sqrt{s_P^2 + s_N^2}}$$

Quality Types	For a Moderate Control
Excellent	$\hat{\beta} \leq -2$
Good	$-2 < \hat{\beta} \leq -1$
Inferior	$-1 < \hat{\beta} \leq -0.5$
Poor	$\hat{\beta} > -0.5$

11


## UPREGULATORS

<b>CDH1</b>	Cadherin 1
<b>C18orf54</b>	Chromosome 18 Open Reading Frame 54
<b>TMEM101</b>	Transmembrane Protein 101
<b>WDR66</b>	Cilia And Flagella Associated Protein 2
<b>FOXA3</b>	Forkhead Box A3
<b>DEFB105A</b>	Defensin Beta 105A
<b>TRIM49</b>	Tripartite Motif Containing 49
<b>ADPRHL1</b>	ADP-Ribosylhydrolase Like 1
<b>ADRB1</b>	Adrenoceptor Beta 1
<b>CHRM3</b>	Cholinergic Receptor Muscarinic 3
<b>PIM3</b>	Pim-3 Proto-Oncogene, Serine/Threonine Kinase
<b>RNF227</b>	Ring Finger Protein 227
<b>HAPLN4</b>	Hyaluronan And Proteoglycan Link Protein 4
<b>BCL2L13</b>	BCL2 Like 13
<b>ANKRD61</b>	Ankyrin Repeat Domain 61
<b>BCL2L2-PABPN1</b>	BCL2L2-PABPN1 Readthrough
<b>AGT</b>	Angiotensinogen
<b>ZDHHC3</b>	Zinc Finger DHHC-Type Palmitoyltransferase 3
<b>TNFRSF19</b>	TNF Receptor Superfamily Member 19
<b>LRRC8C</b>	Leucine Rich Repeat Containing 8 VRAC Subunit C
<b>THNSL2</b>	Threonine Synthase Like 2
<b>HEATR5A</b>	HEAT Repeat Containing 5A
<b>FZD9</b>	Frizzled Class Receptor 9
<b>FAM106B</b>	Family With Sequence Similarity 106 Member B
<b>ITPRID1</b>	ITPR Interacting Domain Containing 1
<b>MYORG</b>	Myogenesis Regulating Glycosidase (Putative)
<b>ERICH2</b>	Glutamate Rich 2
<b>AFF1</b>	ALF Transcription Elongation Factor 1
<b>C17orf100</b>	Chromosome 17 Open Reading Frame 100
<b>ZNF765</b>	Zinc Finger Protein 765
<b>CFAP57</b>	Cilia And Flagella Associated Protein 57

## DOWNREGULATORS

<b>FARP1</b>	FERM, ARH/RhoGEF And Pleckstrin Domain Protein 1
<b>CD63</b>	CD63 Molecule
<b>SIK2</b>	Salt Inducible Kinase 2
<b>GPR50</b>	G Protein-Coupled Receptor 50
<b>SRGAP1</b>	SLIT-ROBO Rho GTPase Activating Protein 1
<b>CA10</b>	Carbonic Anhydrase 10
<b>SPDYE5</b>	Speedy/RINGO Cell Cycle Regulator Family Member E5
<b>MAGED2</b>	MAGE Family Member D2
<b>VCAN</b>	Versican
<b>PSG6</b>	Pregnancy Specific Beta-1-Glycoprotein 6
<b>PPFIA2</b>	PTPRF Interacting Protein Alpha 2
<b>LOC101929627</b>	Putative Exonuclease GOR
<b>ARHGAP27</b>	Rho GTPase Activating Protein 27
<b>UNC119B</b>	Unc-119 Lipid Binding Chaperone B
<b>SARS2</b>	Seryl-TRNA Synthetase 2, Mitochondrial
<b>KLHL32</b>	Kelch Like Family Member 32
<b>PIK3R3</b>	Phosphoinositide-3-Kinase Regulatory Subunit 3
<b>COL6A2</b>	Collagen Type VI Alpha 2 Chain
<b>SLC30A2</b>	Solute Carrier Family 30 Member 2
<b>CCT4</b>	Chaperonin Containing TCP1 Subunit 4
<b>TIFAB</b>	TIFA Inhibitor
<b>EEF1AKMT1</b>	EEF1A Lysine Methyltransferase 1
<b>EIF2AK1</b>	Eukaryotic Translation Initiation Factor 2 Alpha Kinase 1

# GWAS



## ARHGAP27

Rho GTPase Activating Protein 27


“The encoded protein may play a role in clathrin-mediated endocytosis.”

“Increased expression of ARHGAP27 in the brain cortex was associated with decreased risk of PD”

GWAS PD (collection from several association studies MONDO\_0005180)

<b>SCREEN</b>	<b>↑ ARHGAP27 ↓ phospho-<math>\alpha</math>-synuclein</b>
<b>GWAS</b>	<b>↑ ARHGAP27 ↓ PD risk</b>
<b>LITERATURE</b>	<b>↑ <math>\alpha</math>-synuclein ↓ <u>clathrin-mediated endocytosis</u></b>

“Acute introduction of  $\alpha$ -synuclein impairs clathrin-mediated synaptic vesicle endocytosis”




Banks, Susan ML, et al. (2020).

# Identification of genetic modulators of prion uptake via CRISPR screens


Elena De Cecco, PhD

University of Zurich




# Can we identify genes that modulate prion uptake?

SHSY5Y dCas9-VP64



# INTERNALIZATION CHECK



## Sorting and visual inspection of sorted cells



# Genome-wide screen - QC




Davide  
Caredio




Very good replicate correlation of both prion negative and prion positive cells

# Genome-wide CRISPRa screen




# AN UNEXPECTED CANDIDATE: BRS-3

BRS3 is an orphan GPCR expressed in pancreas and in the hypothalamus



BRS3 is poorly characterized and not associated to neurodegeneration

# Pathway analysis



BMP pathway identified in several databases

[explain columns](#)

Reactome Pathways				
pathway	description	count in network	strength	false discovery rate
HSA-201451	Signaling by BMP	7 of 27	1.13	0.0066



WikiPathways				
pathway	description	count in network	strength	false discovery rate
WP1425	Bone morphogenic protein signaling and regulation	5 of 12	1.33	0.0096

Tissue expression (TISSUES)				
tissue	description	count in network	strength	false discovery rate
BTO:0000202	Sense organ	45 of 1124	0.32	0.0125



# Bone Morphogenetic Protein Signalling Pathway



# BMP pathway – identified hits

GENE	SCORE	FUNCTION	
BMPR1B	UP (21.5)	Receptor (S/T kinase)	Form <u>heterotetramers</u>
BMPR2	UP (36)	Receptor (S/T kinase)	
BMP7	DOWN (47)	<u>Secreted ligand</u>	
SMAD1	UP (25)	<u>Transcription factor</u>	Effector SMADs
SMAD5	UP (20.6)	<u>Transcription factor</u>	
SMAD6	DOWN (46)	<u>Transcription factor</u>	Inhibitory SMAD
RUNX2	DOWN (37)	<u>Transcription factor</u>	
RGMA	UP (31)	<u>GPI protein</u>	
AMH	DOWN (31.3)	<u>Secreted ligand</u>	
ACVRL1	UP (45.6)	Receptor (S/T kinase)	
LRIG1	UP (38.7)	EGFR <u>regulator (inhibitor)</u>	Similar function
LRIG2	DOWN (38.7)	EGFR <u>regulator (activator)</u>	
LRIG3	UP (28)	EGFR <u>regulator (inhibitor)</u>	Opposite function


# Their partners: the LRIG brothers

GENE	SCORE	FUNCTION
LRIG1	UP (38.7)	EGFR regulator (inhibitor)
LRIG2	DOWN (38.7)	EGFR regulator (activator)
LRIG3	UP (28)	EGFR regulator (inhibitor)

## LRIG proteins regulate lipid metabolism via BMP signaling and affect the risk of type 2 diabetes


[Carl Herdenberg](#), [Pascal M. Mutie](#), [Ola Billing](#), [Ahmad Abdullah](#), [Rona J. Strawbridge](#), [Ingrid Dahlman](#), [Simon Tuck](#), [Camilla Holmlund](#), [Peter Arner](#), [Roger Henriksson](#), [Paul W. Franks](#) & [Håkan Hedman](#) ✉

LRIG-KO mice are deficient in BMP signalling  
Phenotype is rescued by overexpression of LRIG1  
and LRIG3, but not LRIG2



# Whole Genome-Wide Arrayed CRISPRa Screen to identify genetic modulators of PrP<sup>C</sup> expression

Chiara Trevisan, Hao Wang




# Selection of candidate genes: normalization by the median of the genes


Cut-off criteria: p-value < 0.05    Fold change: < 0.5 or > 2 (=  $\log_2\text{FC} < -1$  or  $> 1$ )

80 Upregulators

451 Downregulators




# Physical location of PrP<sup>C</sup> upregulators




TR-FRET to reproduce the results and exclude false positive

4 replicates per gene


Cut-off criteria: p-value <0.05 Fold change: <0.5 or >2 (= log<sub>2</sub>FC < -1 or >1)





# Transcriptional vs. post-transcriptional modifiers




# Hit validation of PrP<sup>C</sup> upregulators by Western blotting




# Hit validation of PrP<sup>C</sup> downregulators by flow cytometry




No Stain



Wild-type




PRNP






LAPTM4B

## Some of the strongest downregulators of surface PrP<sup>C</sup> are involved in **lysosomal degradation**


- LAPT4B is a lysosomal protein that may mediate the transport of PrPC into lysosomes
- MAGI2 is involved in endocytosis and may perhaps mediate PrPC endocytosis
- Bafilomycin inhibits lysosomal function and suppresses the effect of LAPT4B, MAGI2 and ERICH1 activation



TFEB, a master regulator of lysosomal biogenesis and autophagy, showed up as a PrP<sup>C</sup> downregulator.



# Several genes involved in ECM breakdown downregulate PrP<sup>C</sup>





# CRISPR4ALL

Research with advanced CRISPR libraries



*When all you have is a  
CRISPR library...*



*....everything looks like a  
screenable phenotype*

We are looking for partners! If you have an informative, screenable phenotype, and are willing to apply jointly for competitive funding, you know where I live.